What KERYX BIOPHARMACEUTICALS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Baupost Group LLC/MA | Director | Dec 12 | Disposition to Issuer · D | −65,374,013 | — | — | 0 |
| Cameron Kevin J | Director | Dec 12 | Disposition to Issuer · D | −186,666 | — | — | 0 |
| Morrison Jodie Pope | Interim CEO | Dec 12 | Disposition to Issuer · D | −120,000 | — | — | 0 |
| Heffernan Michael Thomas | Director | Dec 12 | Disposition to Issuer · D | −20,000 | — | — | 0 |
| Enyedy Mark J | Director | Dec 12 | Disposition to Issuer · D | −10,000 | — | — | 0 |
| Rogers Michael W | Director | Dec 12 | Disposition to Issuer · D | −30,000 | — | — | 0 |
| Carberry Christine A. | Chief Operating Officer | Dec 12 | Disposition to Issuer · D | −100,646 | — | — | 0 |
| Gilman Steven C | Director | Dec 12 | Disposition to Issuer · D | −27,333 | — | — | 0 |
| Neylan John F. | Chief Medical Officer | Dec 12 | Disposition to Issuer · D | −148,279 | — | — | 0 |
| Regan Daniel Paul | Director | Dec 12 | Disposition to Issuer · D | −60,000 | — | — | 0 |
| Holmes Scott A | Chief Financial Officer | Dec 12 | Disposition to Issuer · D | −162,956 | — | — | 0 |
| Baupost Group LLC/MA | Director | Dec 11 | Grant / award · A | +4,000,000 | — | — | 65,374,013 |
| Baupost Group LLC/MA | Director | Dec 11 | Grant / award · A | +35,582,335 | $4.63 | +$165M | 61,374,013 |
| Carberry Christine A. | Chief Operating Officer | Dec 11 | Open-market sale · S | −10,469 | $3.22 | −$33.7K | 100,646 |
| Holmes Scott A | Chief Financial Officer | Nov 15 | Sale for tax withholding · S | −1,155 | $2.77 | −$3.2K | 162,956 |
| Neylan John F. | Chief Medical Officer | Nov 15 | Sale for tax withholding · S | −1,156 | $2.77 | −$3.2K | 148,279 |
| Holmes Scott A | Chief Financial Officer | Oct 29 | Sale for tax withholding · S | −1,254 | $3.07 | −$3.85K | 164,111 |
| Neylan John F. | Chief Medical Officer | Oct 29 | Sale for tax withholding · S | −1,253 | $3.07 | −$3.85K | 149,435 |
| Carberry Christine A. | Chief Operating Officer | Oct 18 | Sale for tax withholding · S | −2,040 | $3.29 | −$6.71K | 111,115 |
| Holmes Scott A | Chief Financial Officer | Aug 15 | Sale for tax withholding · S | −1,185 | $3.04 | −$3.6K | 165,365 |
Loading...